Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombo-cythemia

Haematologica

Volumn 93, Issue 7, 2008, Pages 1098-1100

  Borze, Ioana ^a   Mustjokio, Satu ^b   Juvonen, Eeva ^b   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

ET; JAK2V617V, hematopoietic progenitors; Microarray; PV

Indexed keywords

BONE MARROW CELL; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; KARYOTYPE; LETTER; POLYCYTHEMIA VERA; THROMBOCYTHEMIA;

BONE MARROW CELLS; CHROMOSOME ABERRATIONS; CYTOGENETICS; DNA MUTATIONAL ANALYSIS; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; MUTATION; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS;

EID: 46849100475     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12547     Document Type: Letter

References (12)

1. Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 2005;19:1-13.
2. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356: 459-68, Comment in: N Engl J Med 2007;356:444-5.
3. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6.
4. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
5. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Hormila P, et al. Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings. Ann Hematol 1998;77:101-6.
6. Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993; 83:192-7.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
8. Erratum in: Lancet 2005;366:122.
9. Savola S, Nardi F, Scotlandi K, Picci P, Knuutila S. Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenet Genome Res 2007;119:21-6.
10. Scheinin I, Myllykangas S, Borze I, Bohling T, Knuutila S, Saharinen J. CanGEM: mining gene copy number changes in cancer. Nucleic Acids Res Epub 2007 Oct 11.
11. Panani AD. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. Cancer Lett 2007;255:12-25.
12. Espinet B, Puigdecanet E, Florensa L, González L, Salido M, Bellosillo B, et al. Array comparative genomic hybridization reveals an absence of recurrent genomic copy number changes in essential thrombocythemia. Abstract 0098. Haematologica (EHA Annual Meeting Abstract) 2006;91:37.